Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,034 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo 400 mg Clear all
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

NCT02201940
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Diclofenac Capsules to Treat Dental Pain

NCT00985439
View directory record Official record
Conditions
Dental Pain
Interventions
Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib 400 mg, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers

NCT02751359
View directory record Official record
Conditions
Pain
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 1, 2026, 12:57 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891
View directory record Official record
Conditions
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

BAY12-8039: 5 Days for Sinusitis vs Placebo

NCT00492024
View directory record Official record
Conditions
Sinusitis
Interventions
Moxifloxacin (Avelox, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Northport, Alabama • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

NCT03108482
View directory record Official record
Conditions
Acute Post-surgical Pain
Interventions
Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 1, 2026, 12:57 AM EDT
Recruiting Phase 3 Interventional

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
52
States / cities
Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 1, 2026, 12:57 AM EDT
Terminated Phase 3 Interventional Results available

Empiric Therapy of Mucopurulent Cervicitis (MPC)

NCT01072136
View directory record Official record
Conditions
Vaginitis Bacterial, Cervicitis
Interventions
Placebo, Azithromycin, Cefixime
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Birmingham, Alabama • Torrance, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain

NCT01216163
View directory record Official record
Conditions
Pain
Interventions
Novel Ibuprofen, Acetaminophen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 40 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 1 Interventional

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

NCT04027387
View directory record Official record
Conditions
HIV-1-infection
Interventions
TMB-365
Biological
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • Ft. Pierce, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 2 Interventional

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

NCT01126970
View directory record Official record
Conditions
Obesity
Interventions
Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo, Velneperit Placebo, Reduced Calorie Diet
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Santa Rosa, California • Waterbury, Connecticut • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 1, 2026, 12:57 AM EDT
Withdrawn Phase 1 Interventional

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

NCT05596045
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
ASC10, Placebo
Drug
Lead sponsor
Ascletis Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Anniston, Alabama • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

NCT04505397
View directory record Official record
Conditions
Healthy
Interventions
SKL24741, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 1, 2026, 12:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Impact of Sex in the Effect of Dietary Capsaicin on Cardiovascular Health

NCT06363305
View directory record Official record
Conditions
Pre Hypertension, Hypertension
Interventions
Dietary capsules
Dietary Supplement
Lead sponsor
Skidmore College
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

NCT01921205
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
Boulder, Colorado • Orlando, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of SAMe in Patients With Alcoholic Liver Disease

NCT00573313
View directory record Official record
Conditions
Liver Disease, Alcoholic
Interventions
S-adenosylmethionine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

NCT03247517
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 200mg SPN-812, 400mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Dothan, Alabama • Orange, California • Hialeah, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

NCT06250283
View directory record Official record
Conditions
Low Bone Mass
Interventions
Resveratrol, Placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia

NCT06636825
View directory record Official record
Conditions
Hypercapnia
Interventions
Graded hypercapnia, Caffeine, Placebo
Other · Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 2 Interventional Results available

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01090024
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 1, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 1, 2026, 12:57 AM EDT